Recombinant Human Serum Albumin

Phase 1Small molecule

PProtgen Ltd

Recombinant Human Serum Albumin is one of 118 small molecule programs targeting Ascites. It is currently in Phase 1.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

Alzheimer DiseaseActive, not recruiting

Alzheimer's Disease (AD)Completed

CirrhosisActive, not recruiting

AscitesPhase 2/Phase 3

Active, not recruiting

Alzheimer DiseasePhase 1

Active, not recruiting

Alzheimer's Disease (AD)Phase 1

Completed

CirrhosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Preclinical

2 2

Farxiga

AstraZeneca

Preclinical

1 3

Thalomid

Bristol-Myers Squibb

Preclinical

1 4

Revia

Teva

Preclinical

1 5

Cipro

Bayer

Preclinical

1 6

Dobutrex

Eli Lilly

Preclinical

1 7

Azulfidine

Pfizer

Preclinical

1 8

Coreg

Akero Therapeutics

Preclinical

6 9

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

5 10

Cialis

Eli Lilly

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cirrhosis1 trial

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Completed·PProtgen Ltd·Phase 1·NCT05249374·36 enrolled

Phase II1 trial

Phase II/III of Recombinant Human Serum Albumin

Completed·PProtgen Ltd·Phase 2/3·NCT05858853·92 enrolled

Ascites1 trial

Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

Completed·PProtgen Ltd·Phase 2/3·NCT06553456·390 enrolled

Alzheimer's Disease (AD)1 trial

An Open-label, Parallel-group Exploratory Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Recombinant Human Serum Albumin Injection in the Treatment of Mild to Moderate Alzheimer's Disease

Completed·PProtgen Ltd·Phase 1·NCT06489015·30 enrolled

Unspecified1 trial

Recombinant Human Serum Albumin in Healthy Subjects

Completed·PProtgen Ltd·Phase 1·NCT05179265·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Recombinant Human Serum Albumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Human Serum Albumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Human Serum Albumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Protgen Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PProtgen Ltd

Recombinant Human Serum Albumin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cirrhosis1 trial

Phase II1 trial

Ascites1 trial

Alzheimer's Disease (AD)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News